CYTK SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Announces that Cytokinetics Investors Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Cytokinetics, Incorporated due to misleading statements regarding the New Drug Application (NDA) for aficamten, which may have led to investor losses [4][6][8]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in Cytokinetics between December 27, 2023, and May 6, 2025, to discuss their legal rights [1][4]. - There is a deadline of November 17, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Cytokinetics [4]. Group 2: Misleading Statements - The complaint alleges that Cytokinetics made materially false and misleading statements about the NDA submission and approval timeline for aficamten, claiming expected FDA approval in the second half of 2025 without disclosing risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) [6][7]. - During an earnings call on May 6, 2025, it was revealed that the company had discussions with the FDA regarding safety monitoring but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [7]. Group 3: Impact on Investors - As a result of the misleading statements, investors purchased Cytokinetics' common stock at inflated prices and suffered significant losses when the truth was revealed [8].